- Home
- CIK vs AARD Comparison
CIK vs AARD Comparison
Compare CIK & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- AARD
- Stock Information
- Founded
- CIK 1987
- AARD 2017
- Country
- CIK United States
- AARD United States
- Employees
- CIK N/A
- AARD N/A
- Industry
- CIK Finance/Investors Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- AARD Health Care
- Exchange
- CIK Nasdaq
- AARD Nasdaq
- Market Cap
- CIK 154.6M
- AARD 154.9M
- IPO Year
- CIK N/A
- AARD 2025
- Fundamental
- Price
- CIK $2.97
- AARD $12.13
- Analyst Decision
- CIK
- AARD Strong Buy
- Analyst Count
- CIK 0
- AARD 5
- Target Price
- CIK N/A
- AARD $33.00
- AVG Volume (30 Days)
- CIK 115.4K
- AARD 40.9K
- Earning Date
- CIK 01-01-0001
- AARD 08-14-2025
- Dividend Yield
- CIK 9.03%
- AARD N/A
- EPS Growth
- CIK N/A
- AARD N/A
- EPS
- CIK N/A
- AARD N/A
- Revenue
- CIK N/A
- AARD N/A
- Revenue This Year
- CIK N/A
- AARD N/A
- Revenue Next Year
- CIK N/A
- AARD N/A
- P/E Ratio
- CIK N/A
- AARD N/A
- Revenue Growth
- CIK N/A
- AARD N/A
- 52 Week Low
- CIK $2.50
- AARD $4.88
- 52 Week High
- CIK $3.19
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- CIK 56.43
- AARD N/A
- Support Level
- CIK $2.95
- AARD N/A
- Resistance Level
- CIK $2.99
- AARD N/A
- Average True Range (ATR)
- CIK 0.03
- AARD 0.00
- MACD
- CIK -0.00
- AARD 0.00
- Stochastic Oscillator
- CIK 62.50
- AARD 0.00
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.